Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
Updated safety recommendations have been issued as part of the European review evaluating cases of neural tube defects in babies born to mothers who became pregnant while taking dolutegravir. The latest data indicate the risk is smaller than previously thought.
Source:
Medicines and Healthcare products Regulatory Agency